Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines for serious diseases. The company’s expertise in the role of Tissue Factor (TF) in angiogenesis, inflammation, and metastasis has allowed us to develop a unique therapeutic approach to retinal disease and cancer. Led by a seasoned management team, Iconic is advancing its lead candidate, ICON-1, through clinical development for the treatment of wet AMD.